Moreover, Airain Limited has 1.4% invested in AbbVie Inc (NYSE:ABBV).
ABBV has been the topic of a number of recent research reports.
AbbVie Inc. most recently reported earnings per share (EPS) of $1.42 for the June 2017 versus $1.26 in the same quarter previous year, representing 13% growth. Jefferies Group LLC reiterated a "buy" rating and issued a $90.00 target price on shares of AbbVie in a report on Thursday, January 5th. North American Management Corp lifted its holdings in shares of AbbVie by 1.1% in the 1st quarter. The firm has "Buy" rating given on Monday, December 7 by Jefferies. Deutsche Bank maintained it with "Hold" rating and $6 target in Monday, July 17 report. Analysts rating the company a 3 indicate a Hold recommendation. (NYSE:ABBV). According to First Call, the consensus price target for the company is $77.94. (NYSE:ABBV) high level. Roughly 9.16 million shares changed hands compared to the three-month volume average 5.55 million shares. The 50 day moving average was up $15.10 or +20.55% and the 200 day average went up $19.61 or +28.43%. The company has a market capitalization of $141.03 billion, a P/E ratio of 21.76 and a beta of 1.48. The Firm has ATR of 1.64 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price. Goldman Sachs maintained the shares of ABBV in report on Friday, March 10 with "Buy" rating. As of the latest earnings report the EPS was $4.07 and is projected to be $5.52 for the current year with 1,594,094,000 shares now outstanding. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. The dividend payment will be $0.640 per share for the quarter or $2.56 on an annualized basis. The stock recovered 11.11% since its low point and has performed -35.48% year-to-date.
In case of Revenue Estimates, 13 analysts have provided their consensus Average Revenue Estimates for AbbVie Inc.as 6.96 Billion. If you are accessing this story on another publication, it was copied illegally and reposted in violation of USA and worldwide copyright and trademark law. Credit Suisse maintained it with "Hold" rating and $65 target in Wednesday, June 7 report. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. The dividend yield will be $2.92. AbbVie's dividend payout ratio (DPR) is 62.90%. After the recent increase in the stock price, investors might also be looking to see if the stock has entered overbought territory and possibly be primed for a pullback. Visionary Asset Management Inc. lifted its holdings in shares of AbbVie by 3.8% in the 1st quarter. Following the transaction, the insider now owns 96,074 shares in the company, valued at approximately $6,733,826.66. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The stock was sold at an average price of $71.02, for a total value of $6,242,586.98. Following the transaction, the director now owns 15,498 shares in the company, valued at $1,091,834.10. The disclosure for this sale can be found here.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. For the quarter, shares have been noted at 25.45%.
AbbVie Inc. (ABBV) surprised the stock market in its last reported earnings when it earned $1.42 a piece versus the consensus-estimated $1.4. Investec Asset Management LTD lifted its position in AbbVie by 3.6% during the 1st quarter. Legal & General Group Plc lifted its position in shares of AbbVie by 4.1% during the first quarter. British Columbia Investment Mngmt Corporation invested in 0.4% or 728,715 shares. Finally, Iowa State Bank lifted its position in AbbVie by 3.6% during the 1st quarter. The firm owned 130,634 shares of the company's stock after selling 9,929 shares during the quarter. It is positive, as 86 investors sold ABBV shares while 555 reduced holdings. Atwood & Palmer Inc. now owns 2,150 shares of the company's stock worth $140,000 after purchasing an additional 2,000 shares in the last quarter. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
- Nike, Inc. (NKE) Receives Buy Rating from DA Davidson
- Hurricanes Harvey & Irma Affect US Apparel Retailers More Than Restaurants
- How Does Bank of the Ozarks (OZRK) Stack Up Right Now?
- Spartak hit with two charges over ref flare incident
- Census: Nation's median income rose, poverty rate fell in 2016
- Houston Texans quarterback controversy: Does Tom Savage deserve to be pulled out?
- Price Target Analysis Valeant Pharmaceuticals International, Inc. (VRX)
- Sony Announces Limited Edition CoD WWII PS4 Bundle
- Here's What to Focus on - Chevron Corporation (NYSE:CVX)
- Real Madrid announce new Isco deal